ICER Analyses Increasingly Guide US Price Negotiations, Payers Report
Executive Summary
Nearly 65% of respondents reported ICER cost effectiveness reviews are 'likely' or 'extremely likely' to function as a benchmark in price negotiations with manufacturers, according to a recent survey.
You may also be interested in...
ICER Value Framework Update Reaffirms Support For Real-World Evidence
Drug makers have sought a larger role for RWE in ICER's review process; proposed update also includes process to re-evaluate cost-effectiveness evidence after one year.
ICER Value Assessments Could Provide US Standard, Payers, Providers Tell HHS
Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.
Lilly’s 340B Restrictions: Jury Is Still Out On Appropriateness, But Optics Are Bad, HHS Says
Letter from department’s general counsel responds to request from the company for a pre-enforcement advisory opinion. Despite the letter, Lilly maintains its ‘limited distribution program is fully consistent with applicable laws and regulations.’
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: